MyoKardia Launches with $38M in Series A Round | GenomeWeb

NEW YORK (GenomeWeb News) – MyoKardia, a San Francisco-based drug startup, has been launched with $38 million in Series A financing from Third Rock Ventures.

The firm is taking a genetically targeted approach to drug development, using a proprietary drug discovery platform that combines advances in cardiovascular genomics and heart muscle biology research. According to the firm, its approach will "leverage resident expertise in sarcomere genetics, in vivo and in vitro disease models, next-generation biochemical and biophysical assay development, and medicinal chemistry."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.